BioNTech is a biotechnology company focused on developing innovative immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, BioNTech engages in the development of a broad range of product candidates, including neoantigen-targeted therapies and mRNA vaccines. Its oncology pipeline features various candidates in clinical trials, such as BNT111 for advanced melanoma and NEO-PV-01 for non-small cell lung cancer. The company also explores T cell immunotherapies and RiboCytokines to address solid tumors. In addition to its cancer-focused initiatives, BioNTech is advancing mRNA vaccine candidates for infectious diseases, leveraging its expertise in mRNA technology and in-house manufacturing capabilities. The company collaborates with several prominent pharmaceutical firms to enhance its research and development efforts.
InstaDeep Ltd develops and offers artificial intelligence (AI) based decision making systems for enterprise sector. The company was founded in 2014 and is headquartered in London, United Kingdom with additional offices in Paris, France; Tunis, Tunisia; Nairobi, Kenya; and Lagos, Nigeria.
Kite - TCR therapy
Acquisition in 2021
TCR therapy is a type of cellular immunotherapy designed to redirect the patient’s immune system in order to recognize and target tumors.
Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.